METABOLIC MONITORING TOOL* (1st year)

	Please complete whenever	er a dient begi	ins a first t	rial of an antipsy	chotic or when	switching	antipsychotics		
Client Name (last, first)		DOB (DOB (dd/mm/yyyy)		PARIS ID:		PHN:		
Atypical:				tart Date (d/m/y): Stop Date (d/m/y):					
Atypical:	Star	Start Date (d/m/y): Stop Date (d/m/y):							
Atypical:			Star	t Date (d/m/y):		Sto	p Date (d/m/y)	:	
Risks: Smoking Smale history diabete Other (list)		original, Hispar		essure			ctory of gestation		isorder
Comments:									
Metabolic Para	meters								
Parar (Normal	neter Values)	True Pre- treatment Baseline*	Current Baseline	1 month	2 month	3 month	6 month	9 month	12 month
Te	est Date (dd/mm/yyyy): >			NOMES DE CONTRACTOR DE CONTRAC					
Height (cr	n):					a transita	16.4.4.7ad		467.07
Weight (k	g):								
Waist Circumferen (At the level of the umbilio									
Blood Pressu	re: < 130/85						AND ST	J. 33.544.	
Fasting Plasma Gluco	se: < 5.6 mmol/L				3 N				
Fasting Total Cholester	rol: < 5.2 mmol/L								
Fasting LDL	-C: < 3.4 mmol/L								
Fasting HDL	-C: M: > 1.0 mmol/L F: > 1.3 mmol/L								
Total Cholester HDL-C Rat	· · · · · · · · · · · · · · · · · · ·								
Fasting Triglyceride	es: < 1.7 mmol/L								
Other (eg. HgbA1C, OGTT etc.)	:								
F	Physician Initials: >								
Interventions: (continue checking as conducted throughout the year) Discuss metabolic risks Discuss signs and symptoms of diabetes Discuss signs and symptoms of DKA Discuss smoking cessation			s 0 F	□ Discuss diet □ Risk/benefit assessment □ Switch antipsychotic medication □ Discuss physical activity □ Refer to rehab/groups for lifestyle management □ Discuss physical activity □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic, diabetes clinic □ Risk/benefit assessment □ Switch antipsychotic medication □ Switch antipsychotic medication □ Refer to rehab/groups for lifestyle □ Refer to specialized services (via lipid dinic, diabetes clinic □ Risk/benefit assessment □ Switch antipsychotic medication □ Switch antipsychotic medication □ Refer to rehab/groups for lifestyle □ Refer to specialized services (via lipid dinic, diabetes clinic □ Risk/benefit assessment □ Switch antipsychotic medication □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic, diabetes clinic □ Refer to specialized services (via lipid dinic lipi				b.	
Comments:									

* See Guidelines For Metabolic Monitoring

WAIST CIRCUMFERENCE: Ethnic Specific Values

Central obesity is most easily measured by waist circumference using the guidelines in the following table which are gender and ethnic-group (not country of residence) specific. The consensus group acknowledges that there are pragmatic cut-points taken from various different data sources and that better data will be needed to link these to risk.

Ethnic Group		Waist Circumference *		
Europids	Male	≥ 94 cm		
In USA, the ATP III values (102 cm male; 88 cm female) are likely to continue to be used for clinical purposes	Female	≥ 80 cm		
South Asians	Male	≥ 90 cm		
Based on a Chinese, Malay and Asian-Indian population	Female	≥ 80 cm		
Chinese	Male	≥ 90 cm		
	Female	≥ 80 cm		
Japanese	Male	≥ 85 cm		
	Female	≥ 90 cm		
Ethnic South and Central Americans	Use South Asian recommendations until more specific data are available			
Sub-Saharan Africans	Use European data until more specific data are available			
Eastern Mediterranean and Middle East (Arab) populations	Use European data until more specific data are available			

^{*} In future epidemiological studies of populations of Europid origin, prevalence should be given using both European and North American cut-points to allow better comparisons.

Although a higher cut-point is currently used for all ethnic groups in the USA for clinical diagnosis, it is strongly recommended that for epidemiological studies and, whatever possible, for case detection, ethnic group specific cut-points should be used for people of the same ethnic group wherever they are found. Thus the criteria recommended for Japan would also be used in expatriate Japanese communities, as would those for South Asian males and females regardless of place and country of residence.

Note: For Indigenous ethnic group, they will follow the same cut-points as South Asians.